{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T08:39:00Z","timestamp":1771576740306,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study aimed to evaluate and compare the disease burden of pharmacovigilance-related events in European countries, to identify the factors related to pharmacovigilance-related inputs in various countries, and to analyze and compare the comprehensive benefits of pharmacovigilance-related events in various countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using the Global Burden of Disease Study 2021 database, we combined information on adverse effects of medical treatment and drug use disorders to identify all pharmacovigilance-related events. We used principal component analysis to synthesize six first-level indicators to compare the burden of disease in each country in each year. We used data envelopment analysis to compare the efficiency of pharmacovigilance in each country.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 2021, the Quality of care index for pharmacovigilance-related events was highest in Northern and Western European countries. Looking at data from 1990 to 2021, the change node of this index in most countries occurred around 2000 to 2010, and the value changed steadily. Countries with relatively low investment in health resources and less experience in the supervision of adverse drug reactions have higher comprehensive benefits of nursing for pharmacovigilance-related events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The effect of the development of a system for pharmacovigilance has a hysteresis. The disease burden is affected by various factors such as population aging, human resource investment, and medical and health needs, and the policy is highly dominant.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1592957","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T05:33:05Z","timestamp":1751002385000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacovigilance-related events, disease burden and overall efficiency of care in european countries, 1990-2021"],"prefix":"10.3389","volume":"16","author":[{"given":"Lin","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzhi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zimeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"B1","volume-title":"Institute for Health Metrics and Evaluation","year":"2007"},{"key":"B2","volume-title":"Creation of a better medication safety culture in Europe: building up safe medication practices","author":"Airaksinen","year":"2007"},{"key":"B3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/YCO.0000000000000610","article-title":"Introducing the national drug early warning system","volume":"33","author":"Artigiani","year":"2020","journal-title":"Curr. Opin. Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"555598","DOI":"10.19080\/GJARM.2017.02.555598","article-title":"Findings from a large-scale empirical research on substance abuse prevention in Greece","volume":"2","author":"Dritsas","year":"2017","journal-title":"GJARM"},{"key":"B5","volume-title":"Institute for Health Metrics and Evaluation","year":"2020"},{"key":"B6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/bmjqs-2019-010206","article-title":"Economic analysis of the prevalence and clinical and economic burden of medication error in England","volume":"30","author":"Elliott","year":"2021","journal-title":"BMJ Qual. Saf."},{"key":"B7","first-page":"104","article-title":"European Union to launch new pharmacovigilance regulations in July 2012","volume":"29","year":"2012","journal-title":"Chin. J. Drug Eval."},{"key":"B8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.13688\/j.cnki.chr.2019.19027","article-title":"Reflection and enlightenment of a value-based approach on patient safety economic research","volume":"22","author":"Fu","year":"2019","journal-title":"Chin. Health Resour."},{"key":"B9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s43441-022-00415-y","article-title":"A systematic review of pharmacovigilance systems in developing countries using the WHO pharmacovigilance indicators","volume":"56","author":"Garashi","year":"2022","journal-title":"Ther. Innov. Regul. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2021","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1080\/03007995.2017.1336082","article-title":"Pharmacovigilance in Russia: current state of affairs, challenges, and prospects","volume":"33","author":"Gildeeva","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"B12","unstructured":"Data resources GHDx\n          \n          \n          2021"},{"key":"B13","unstructured":"2022"},{"key":"B14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in asia, the Middle East and north africa: data from global burden of disease 2009-2019","volume":"75","author":"Golabi","year":"2021","journal-title":"J. Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"484","DOI":"10.12968\/bjon.2013.22.8.484","article-title":"Nurses must report adverse drug reactions","volume":"22","author":"Griffith","year":"2013","journal-title":"Br. J. Nurs."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0292348","DOI":"10.1371\/journal.pone.0292348","article-title":"Global and regional quality of care index (QCI) by gender and age in oesophageal cancer: a systematic analysis of the Global Burden of Disease Study 1990\u20132019","volume":"18","author":"Iezadi","year":"2023","journal-title":"PLOS ONE"},{"key":"B17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/145507259501201s13","article-title":"The EU challenge: new organization and culture around psychotropic prescription drugs in the nordic count","volume":"12","author":"Jensen","year":"1965","journal-title":"Nord. Alkoholtisdkrift Nord. Alcohol Stud."},{"key":"B18","article-title":"A prospective study on detection of Drug Interactions, improving drug safety access and therapeutic outcome in a tertiary care teaching hospital","volume":"9","author":"Krupa","year":"2021","journal-title":"Int. J. Creative Res. Thoughts"},{"key":"B19","first-page":"1","article-title":"National burden of preventable adverse drug events associated with inpatient injectable medications: healthcare and medical professional liability costs","volume":"5","author":"Lahue","year":"2012","journal-title":"Am. Health Drug Benefits"},{"key":"B20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/PTS.0000000000001136","article-title":"The additional cost of perioperative medication errors","volume":"19","author":"Langlieb","year":"2023","journal-title":"J. Patient Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s11096-024-01738-6","article-title":"Global trends in pharmacovigilance-related events: a 30-year analysis from the 2019 global burden of disease study","volume":"46","author":"Lin","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3969\/j.issn.1671-8879.2017.03.014","article-title":"Evaluation on underground road transportation engineering design project based on data envelopment analysis-all databases","volume":"37","author":"Liu","year":"2017","journal-title":"J. Chang\u2019An Univ. Nat. Sci. Ed."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.35248\/2329-6887.20.8.286","article-title":"The beginning of pharmacovigilance in Bosnia and Herzegovina","volume":"8","author":"Martin","year":"2020","journal-title":"J. Pharmacovigil."},{"key":"B24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1742-7843.2007.00141.x","article-title":"Educating European (junior) doctors for safe prescribing","volume":"101","author":"Maxwell","year":"2007","journal-title":"Basic and Clin. Pharmacol. and Toxicol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/001857870403900706","article-title":"The $181,000 adverse drug reaction","volume":"39","author":"Mcdonnell","year":"2004","journal-title":"Hosp. Pharm."},{"key":"B26","article-title":"Health at a glance: Europe 2018","year":"2018"},{"key":"B27","unstructured":"An official website of the European Union\n          \n          \n          2014"},{"key":"B28","first-page":"112","article-title":"Pharmacovigilance and drug safety evaluation","volume-title":"Proceedings of the sixth national congress of toxicology of the Chinese society of toxicology","author":"Qin","year":"2013"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.2147\/DDDT.S466904","article-title":"Effectiveness of spironolactone in reducing osteoporosis and future fracture risk in middle-aged and elderly hypertensive patients","volume":"18","author":"Song","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"B30","first-page":"81","article-title":"Analysis of trends in voluntary reporting of adverse drug reactions in the French pharmacovigilance system","author":"Tian","year":"2007","journal-title":"Chin. J. Pharmacovigil."},{"key":"B31","unstructured":"Uppsala monitoring Centre\n          \n          \n          2023"},{"key":"B32","article-title":"Analysis of the world situation","volume-title":"Report of the international narcotics control board for 2014","year":"2015"},{"key":"B33","first-page":"176","article-title":"Progress in voluntary reporting modalities for the monitoring of adverse drug reactions","author":"Wang","year":"1996","journal-title":"Chin. Pharm. J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.13936\/j.cnki.cjdd1992.2015.06.020","article-title":"Global burden of disease attributable to illicit drug use and dependence: findings from the global burden of disease study 2010","volume":"24","author":"Wang","year":"2015","journal-title":"Chin. J. Drug Dependence"},{"key":"B35","unstructured":"2020"},{"key":"B36","doi-asserted-by":"publisher","first-page":"614","DOI":"10.46234\/ccdcw2023.118","article-title":"Understanding the effects of iatrogenic management on population health: a medical innovation perspective","volume":"5","author":"Yang","year":"2023","journal-title":"China CDC Wkly."},{"key":"B37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/14737167.2023.2267766","article-title":"The impact of under-investment on health in southern and central eastern European countries","volume":"24","author":"Yfantopoulos","year":"2023","journal-title":"Expert Rev. Pharmacoeconomics and Outcomes Res."},{"key":"B38","first-page":"1159","article-title":"World health organization pharmacovigilance indicators and their application","volume":"35","author":"Zeng","year":"2016","journal-title":"Her. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14740338.2022.1998451","article-title":"Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries","volume":"21","author":"Zografos","year":"2022","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1592957\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T05:33:14Z","timestamp":1751002394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1592957\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":39,"alternative-id":["10.3389\/fphar.2025.1592957"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1592957","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"article-number":"1592957"}}